When B Cells Go Bad: Infection, Inflammation and Chronic B Cell Stimulation Karen S. Anderson MD PhD Associate Professor, Biodesign Institute Arizona State University Mayo Clinic Arizona Conflicts of Interest • I serve on the advisory board and have received consultant fees and stock options with Provista Dx. • No off-label clinical diagnostics or therapeutics will be discussed. W. Michael Kuehl & P. Leif Bergsagel, 2002 Monoclonal Gammopathy of Undetermined Signficance • 3.2% of adults over the age of 50; 6.6% of adults over age 80 • Premalignant disease that can transition to myeloma; average 2-15 years, rate 1% per year • Over 90% of patients with MM have a premalignant plasma cell disorder • 50% Ig translocations; 50% hyperdiploid – Errors in switch recombination and somatic hypermutation of the B cell • Likely due to an abnormal response to antigenic stimulation Chronic Infections and Antibodies • EBV, HHV-8, HCV, (CMV), H. pylori are associated with B cell lymphoma and B cell chronic lymphocytic leukemia – what about myeloma? • Ig in HCV-positive myeloma patients can target the virus • ~20% of MGUS and myeloma Abs target infectious antigens (ASH 2013) • Would treatment of chronic infections also prevent or treat MGUS? Chronic Infections not Associated with MGUS Bida and Rajkumar Mayo Clin Proc 2009 How B cells Proliferate in response to infection Moir and Fauci, Nat Rev Immunol 2009 Antibody structure: Ligands (antigens) • What is the specificity of antibodies? • What is the diversity of antibodies? When Ig genes rearrange, there are >1011 potential molecules To facilitate research, DNASU stores over 162,000 plasmids and distributes these to researchers in 37 states and 38 countries Nucleic Acid-Programmable Protein Array (NAPPA) Proteomics: the study of all of the proteins in the human body We use plasmids to make over 10,000 human proteins By putting these plasmids on a glass slide (NAPPA) we can make and study over 10,000 proteins at one time 1. Print Plasmids Protein Expression … • • • Replicate arrays of candidate proteins 2. Express & capture proteins Find antibodies in patients’ blood NAPPA Array Production and Screening Gene Cloning Bacterial plating DNA preparation Array Printing Antigen array Add patient serum p53 Serologic Biomarkers for HPV+ Cancer Human papilloma virus (HPV16): ~70% of oropharyngeal cancers Emerging epidemic in US and Europe HPV Genome: 8 ORFs Diagnosis Prognosis NE2, p<0.001 0.75 0.50 0.25 NE2 positive NE2 negative 0.00 Proportion surviving 1.00 Kaplan-Meier survival estimates 0 12 Number at risk NE2 positive 84 NE2 negative 13 75 9 24 36 48 Follow-up time (months) 66 6 59 4 33 3 60 10 1 Identification of the Targets of Antibodies • Protein microarrays are now used to test >10,000 proteins for antibody targets • Large gene collections can be leveraged for rapid protein display • We are developing pathogen-specific arrays to identify antibodies in blood • We need to measure the antibody IMMUNOME to understand the pathogenesis of MGUS What is the diversity of Antibodies? Can we detect specific Ig rearrangements? DNA Origami nanostructure design Hao Yan and Joe Blattman, Biodesign Overall strategy to obtain linked RNA sequences from single cells. Conclusions Antibodies have extraordinary sequence diversity There are emerging technologies for quantitating that diversity By linking single-cell RNA capture with next-gen sequencing, we may be able to: Identify early events (?pre-MGUS) of loss of diversity Rapidly generate patient-specific probes for molecular detection of rearrangements Acknowledgements ASU Biodesign Institute Anderson Lab Joseph Blattman Julia Cheng Hao Yan Ting Li Josh LaBaer Rizwan Alam Benjamin Katchman Ji Qiu Krishna Sundaresan Garrick Wallstrom Laura Gonzalez Diego Chowell Jin Park Shay Ferdosi Fernanda Festa Hans Frykman I.Purushothaman Fernando Hernandez Mayo Oncology Robert Brown Don Northfelt Alison Goulder Doug Lake Jack Resnik Barb Pockaj Peter Chang Michael Barrett Our Patients NCI/Early Detection Research Network Zicarelli Foundation